Refine your search
Collections
Co-Authors
Journals
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Yadav, Ashok
- Essential Immunonutrients in COVID-19: An Evidence-Based Review
Abstract Views :213 |
PDF Views:0
Authors
Affiliations
1 President- Medical & Regulatory Affairs Aristo Pharmaceuticals Private Limited, Mumbai, IN
2 Assistant General Manager- Medical, Scientific Department, Aristo Pharmaceuticals Private Limited, IN
3 Sr. Scientific Executive- Scientific Department, Aristo Pharmaceuticals Private Limited, IN
1 President- Medical & Regulatory Affairs Aristo Pharmaceuticals Private Limited, Mumbai, IN
2 Assistant General Manager- Medical, Scientific Department, Aristo Pharmaceuticals Private Limited, IN
3 Sr. Scientific Executive- Scientific Department, Aristo Pharmaceuticals Private Limited, IN
Source
The Indian Practitioner, Vol 74, No 6 (2021), Pagination: 20-26Abstract
A ‘well-fed’ immune system is extremely important to ensure it performs the function of protecting against the viral offense. Various nutrients and minerals play a vital role in maintaining the integrity and function of the immune system. Among the various nutrients and minerals, vitamin C, vitamin D, and zinc stand out for having immune-modulatory functions which are demonstrated in a substantial body of evidence. In the ongoing pandemic of COVID-19, nutrients that can optimize the immune system to prevent or lower the risk of severe disease progression are very essential. Medical literature shows that deficiency of one or more of these nutrients may affect the immunity status of an individual and may predispose a person to an adverse prognosis of COVID-19. Therefore, adequate intake of vitamin C, D, and zinc may present as a promising tool in prehabilitation with immunonutrition for COVID-19 prevention and management. This review provides a comprehensive overview of the role of vitamin C, D, and zinc as an immunomodulatory agent in COVID-19 management.Keywords
Vitamin C, vitamin D, zinc, immunity, immunonutrition, COVID-19
References
- Mahalmani VM, Mahendru D, Semwal A, Kaur S, Kaur H,
- Sarma P, et al. COVID-19 pandemic: A review based on current evidence. Indian J Pharmacol. 2020 Mar-Apr;52(2):117-129.
- Lai CC, Shih TP, Ko WC, Tang HJ and Hsueh PR. Severe
- acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International journal of antimicrobial
- agents. 2020;55(3), p.105924.
- Chowdhury MA, Hossain N, Kashem MA, Shahid MA,
- Alam A. Immune response in COVID-19: A review. J Infect
- Public Health. 2020;13(11):1619-1629.
- Maladkar M, Tekchandani MC, Karchodi MA. COVID-19
- Treatment: Current and Emerging Options. The Indian
- Practitioner. 2020;73(6):37-41.
- Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe? Life Sci. 2020;256:117900.
- Zhong J, Tang J, Ye C, Dong L. The immunology of
- COVID-19: is immune modulation an option for treatment?
- The Lancet Rheumatology. 2020;2(7):e428-e436.
- Calder PC. Nutrition, immunity and COVID-19. BMJ
- Nutrition, Prevention & Health. 2020; 3(1), p.74.
- Derbyshire E, Delange J. COVID-19: is there a role for immunonutrition, particularly in the over 65s? BMJ Nutrition,
- Prevention & Health. 2020;3(1):100.
- Burns JJ,. Missing step in man, monkey and guinea pig
- required for the biosynthesis of L-ascorbic acid. Nature.
- ;180(4585):pp.553-553.
- Schleicher RL, Carroll MD, Ford ES, and Lacher DA.. Serum
- vitamin C and the prevalence of vitamin C deficiency in the
- United States: 2003–2004 National Health and Nutrition
- Examination Survey (NHANES). The American journal of clinical nutrition. 2009;90(5): pp.1252-1263.
- Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in
- humans. Am J Clin Nutr. 1999; 69(6):1086-107.
- Maxfield L, Crane JS. Vitamin C Deficiency. [Updated 2020
- Jul 2]. In: StatPearls [Internet]. [cited 2021 Jun 09] Available
- from: https://www.ncbi.nlm.nih.gov/books/NBK493187/
- Carr AC and Maggini S. Vitamin C and immune function.
- Nutrients.2017; 9(11), p.1211.
- Carr AC, Rowe S. The Emerging Role of Vitamin C in the
- Prevention and Treatment of COVID-19. Nutrients. 2020;
- (11):3286.
- Holford P, Carr AC, Jovic TH, Ali SR, Whitaker IS, Marik PE,
- et al. Vitamin C—An Adjunctive Therapy for Respiratory
- Infection, Sepsis and COVID-19. Nutrients. 2020;12(12):3760.
- Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C,
- Farthing CA, et al. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. Journal of translational
- medicine. 2014; 12(1), pp.1-10.
- Nathens AB, Neff MJ, Jurkovich GJ, Klotz P, Farver K,
- Ruzinski JT, et al. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients.
- Annals of surgery. 2002;236(6):814.
- Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J.
- Hydrocortisone, vitamin C, and thiamine for the treatment
- of severe sepsis and septic shock: a retrospective before-after
- study. Chest. 2017;151(6):1229-38.
- Crimi E, Liguori A, Condorelli M, Cioffi M, Astuto M,
- Bontempo P, et al. The beneficial effects of antioxidant supplementation in enteral feeding in critically ill patients: a
- prospective, randomized, double-blind, placebo-controlled
- trial. Anesthesia & Analgesia. 2004;99(3):857-63.
- Feyaerts AF and Luyten W. Vitamin C as prophylaxis and
- adjunctive medical treatment for COVID-19? Nutrition. 2020;
- , p.110948.
- Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treat-ment and prevention. Rev Endocrine
- Metab Disord. 2017;18:153–65
- Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. Journal of infection and public
- health. 2020;13(10): 1373-1380
- Grant WB, Al Anouti F, Moukayed M. Targeted 25- hydroxyvitamin D concentration measurements and vitamin
- D3 supplementation can have important patient and public
- health benefits. Eur J Clin Nutr. 2020;74:366–76.
- Sassi F, Tamone C and D’Amelio P. Vitamin D: nutrient,
- hormone, and immunomodulator. Nutrients. 2018;10(11),
- p.1656.
- Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP.
- Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev. 1996;10(2):142-53.
- Li YC. Vitamin D regulation of the renin–angiotensin system. Journal of cellular biochemistry. 2003;88(2):327-31.
- Zittermann A, Gummert JF. Nonclassical vitamin D actions. Nutrients. 2010;2(4):408-25.
- Lai YH, Fang TC. The pleiotropic effect of vitamin D. ISRN nephrology. 2013; Article ID 898125
- Kalia V, Studzinski GP, Sarkar S. Role of vitamin D in regulating COVID-19 severity—An immunological perspective. Journal of Leukocyte Biology. J Leukoc Biol. 2021;1–11
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
- Sharifi A, Vahedi H, Nedjat S, Rafiei H, Hosseinzadeh-Attar MJ. Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: A randomized place bo-controlled trial. APMIS. 2019; 127:681–687.
- Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients. 2020;12(4):988.
- Bergman P, Lindh ÅU, Björkhem-Bergman L, Lindh JD. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PloS one. 2013;8(6):e65835.
- Charan J, Goyal JP, Saxena D, Yadav P. Vitamin D for prevention of respiratory tract infections: A systematic review and meta-analysis. Journal of pharmacology & pharmacotherapeutics. 2012;3(4):300.
- Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356.
- Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, et al. Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebocontrolled, study (SHADE study). Postgraduate medical journal. Postgrad Med J 2020;0:1–4.
- Saper RB, Rash R. Zinc: an essential micronutrient. American family physician. 2009;79(9):768.
- Zinc Deficiency in Humans affecting Immune System [Internet]. [cited 2021 Jun 06]. Available from: https://indiacsr.in/zinc-deficiency-humans-affecting-immune-system/
- Yanagisawa H. Zinc deficiency and clinical practice. Japan Medical Association Journal. 2004;47(8):359-64.
- Chasapis CT, Ntoupa PS, Spiliopoulou CA, Stefanidou ME. Recent aspects of the effects of zinc on human health. Archives of toxicology. 2020;94:1443-60.
- Prasad AS. Zinc in human health: effect of zinc on immune cells. Molecular medicine. 2008;14(5):353-7.
- Berger A. What does zinc do? BMJ. 2002;325(7372):1062.
- Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI, et al. Zinc and respiratory tract infections: Perspectives for COVID-19. International journal of molecular medicine. 2020;46(1):17-26.
- Prasad AS, Beck FW, Bao B, Fitzgerald JT, Snell DC, Steinberg JD, et al. Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress. The American journal of clinical nutrition. 2007;85(3):837-44.
- Johnstone J, Roth DE, Guyatt G, Loeb M. Zinc for the treatment of the common cold: a systematic review and meta-analysis of randomized controlled trials. Cmaj. 2012;184(10):E551-61.
- Carlucci P, Ahuja T, Petrilli CM, Rajagopalan H, Jones S, Rahimian J. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. MedRxiv. 2020.
- Frontera JA, Rahimian JO, Yaghi S, Liu M, Lewis A, de Havenon A, et al. Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study. Res Sq [Preprint]. 2020;rs.3.rs-94509.
- COVID-19 Treatment Guidelines [Internet]. [cited 2021 Jun 06]. Available from: https://www.covid19treatmentguidelines.nih.gov/supplements/zinc/
- From Darkness to Light : Clinical Insights on Melatonin
Abstract Views :83 |
PDF Views:0
Authors
Affiliations
1 Medical & Regulatory Affairs, Aristo Pharmaceuticals Private Limited, 23-A Shah Industrial Estate, Andheri, Mumbai, IN
2 Scientific Department, Aristo Pharmaceuticals Private Limited, IN
1 Medical & Regulatory Affairs, Aristo Pharmaceuticals Private Limited, 23-A Shah Industrial Estate, Andheri, Mumbai, IN
2 Scientific Department, Aristo Pharmaceuticals Private Limited, IN
Source
The Indian Practitioner, Vol 74, No 8 (2021), Pagination: 30-36Abstract
Melatonin also known as ‘sleep hormone’ is synthesized and released from the pineal gland in response to the luminous information. Melatonin primarily contributes to the regulation of biological rhythms and induction of sleep. Apart from this, due to its inherent anti-oxidant property, it is known to impart protection to various tissues. In addition, it also exhibits multiplicity of physiological effects all over the body. At therapeutic level, Melatonin is used for the management of primary as well as secondary sleep disorders, jet lag, and synchronization of cardiac rhythms. Additionally, due to its pleiotropic benefits it is used in various disorders.Keywords
Melatonin, Sleep Disorders, Pleiotropic Benefits, Therapeutic Benefits.References
- Chowdhury I, Maitra S. Melatonin: Fifty Years of Scientific Journey from the Discovery in Bovine Pineal Gland to Delineation of Functions in Human, Indian Journal of Biochemistry & Biophysics.2008; 45:289-304.
- Pevet P. Melatonin Dialogues in Clinical Neuroscience. 2002; 4:57-72.
- Tordjman S, Chokron S, Delorme R, et al. Current Neuropharmacology. 2017; 15:434- 443.
- Emet M, Ozcan H, Yayla M, et al. A Review of Melatonin, Its Receptors and Drugs. Eurasian J Med. 2016; 48:135-41.
- Feingold KR, Anawalt B, Boyce A, et al. Physiology of the Pineal Gland and Melatonin – Endotext. 2000.
- Srinivasan V, Trahkt I, Spence D, et al. Melatonin and melatonergic drugs on Sleep: possible mechanisms of action. International Journal of Neuroscience. 2009; 119:821-846.
- Khullar A. The Role of Melatonin in the Circadian Rhythm Sleep-Wake Cycle. Psychiatric Times. 2012; 29:1-8.
- Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation British Journal of Pharmacology. 2018; 175:3190–3199.
- ZizhenXie, Fei Chen, William A, et al. A review of sleep disorders and melatonin. Neurological Research. 2017:1-8.
- Shechter A, Lespérance P, Ying Kin N, et al. Nocturnal polysomnographic sleep across the menstrual cycle in premenstrual dysphoric disorder Sleep Med. 2012;13:1071–1078.
- Scheer F, Morris C, Garcia J, et al. Repeated Melatonin Supplementation Improves Sleep in Hypertensive Patients Treated with Beta-Blockers: A Randomized Controlled TrialSleep. 2012; 35:1395–1402.
- Lemoine J, Nir T, Laudon M, et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007; 16:372-380.
- Luthringer R, Muzet M, Zisapel N, et al. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia IntClinPsychopharmacol. 2009; 24:239-249.
- Wade A G, Ford I, Crawford G, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007; 23:2597-2605.
- Roberto C, Mendonça L, Nicolas A, et al. The benefits of four weeks of melatonin treatment on circadian patterns in resistance-trained athletes. Chronobiology International. 2015; 32:1125–1134.
- Mundey K, Benloucif S, Harsanyi K, et al. Phase-Dependent Treatment of Delayed Sleep Phase Syndrome with Melatonin. Sleep. 2005; 28:1271-1278.
- Dahlitz M, Alvarez B, Vignau J, et al. Delayed sleep phase syndrome response to melatonin. Lancet. 1991; 337:1121-1124.
- Kayumov L, Brown G, Jindal R, et al. A Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effect of Exogenous Melatonin on Delayed Sleep Phase Syndrome. Psychosom Med. 2001; 63:40e8.
- Haghighi K S, Aminian O, Pouryaghoub G, et al. Efficacy and hypnotic effects of melatonin in shift-work nurses: double-blind, placebo-controlled crossover trial J Circadian Rhythms. 2008; 6:1-5.
- Sack R, Auckley D, Auger R, et al. Circadian Rhythm Sleep Disorders: Part I, Basic Principles, Shift Work and Jet Lag Disorders. Sleep. 2007; 30:1460-83.
- Herxheimer A, Petrie K. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002:1-9.
- Petrie K, Dawson A, Thompson L, et al. A Double-Blind Trial of Melatonin as a Treatment for Jet Lag in International Cabin Crew. Biol Psychiatry. 1993; 33:526-30.
- McCarter S, Boswell C, St. Louis E, et al. Treatment outcomes in REM sleep behavior disorder. Sleep Med. 2013; 14:237–242.
- McGrane I, Leung J, St. Louis E, et al.Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med. 2015; 16:19–26.
- Kunz D, Mahlberg R. A two-part, double-blind, placebocontrolled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010; 19:591-596.
- Sack R, Brandes R, Kendali A, et al. Entrainment of freerunning circadian rhythms by melatonin in blind people. N Engl J Med. 2000; 343:1070-1077.
- Hack L, Lockley S, Arendt J, et al. The Effects of Low-Dose 0.5-mg Melatonin on the Free-Running Circadian Rhythms of Blind Subjects. J Biol Rhythms.2003;18:420-429.
- Rockville. AHRQ Evidence Report Summaries. Agency for Healthcare Research and Quality (US); 1998-2005.
- Tian Li, Shuai J, Mengzhen H, et al. Exogenous melatonin as a treatment for secondary sleep disorders: a systematic review and meta-analysis Front Neuroendocrinol. 2019; 52:22-28.
- Cardinali D, Brusco L, Liberczuk C, et al. The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett. 2002; 23:20-3.
- Furio A, Brusco L, Cardinali D. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J. Pineal Res. 2007; 43:404-409.
- Zaslavskaia R, Komarov F, Shakirova A, et al. Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension. Klin Med. 2000; 78:41-44.
- Dowling G, Mastickb, Colling E, et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med. 2005; 6:459-466.
- Peled N, Shorer Z, Peled E, et al. Melatonin for sleep disturbances in Parkinson’s disease. Epilepsia. 2001;42(9):1208-1210.
- Dolberg O, Hirschmann S, Grunhaus H. Melatonin for the Treatment of Sleep Disturbances in Major Depressive Disorder Am. J.Psychiatry. 1998; 155:1119-1121.
- Leppamaki S, Partonen T, Vakkuri O, et al. Effect of controlled-release melatonin on sleep quality, mood, and quality of life in subjects with seasonal or weather-associated changes in mood and behavior. Eur. Neuropsychopharmacology. 2003; 13:137-145.
- Weiss M, Wasdell M, Bomben M, et al. Sleep Hygiene and Melatonin Treatment for Children and Adolescents with ADHD and Initial Insomnia. J. Am. Acad. Child Adolesc. Psychiatry. 2006; 45:512-519.
- Carminati G, Deriaz N, Bertschy G. Melatonin in the treatment of chronic sleep disorders in adults with autism: a ret rospective study. Swiss Med. Wkly. 2009; 139:293-296.
- Braam W, Smits M G, Didden R, et al. Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis. Developmental Medicine and Child Neurology. 2009; 51:340-349.
- Mahmood D. Pleiotropic Effects of Melatonin. Drug Res (Stuttg). 2019; 69:65-74.
- Long R, Zhu Y, Zhou S. Therapeutic role of melatonin in migraine prophylaxis: A systematic review. Medicine (Baltimore). 2019;98: e14099.
- Lyon C, Langner S. PURLs: Consider melatonin for migraine prevention. J FamPract. 2017; 66:320-322.
- Lawson K. Is there a role for melatonin in fibromyalgia? AIMS Molecular Science, 2019;6:73-86.
- Miroddi M, Bruno R, Galletti F, et al. Clinical pharmacology of melatonin in the treatment of tinnitus: a review. Eur J ClinPharmacol. 2015; 71:263-70.
- Lundmark P, Pandi-Perumal S, Srinivasan V, et al. Role of melatonin in the eye and ocular dysfunctions. Visual Neuroscience, 2006; 23:853-862.
- Rosenstein R, Pandi-Perumal, S, Srinivasan V, et al. Melatonin as a therapeutic tool in ophthalmology: implications for glaucoma and uveitis. J. Pineal Res. 2010; 49:1–13.
- Awad-Alkoziv H. Melatonin and melanopsin in the eye: friends or foes? An Real Acad Farm. 2019; 85:49-59.
- Siah KT, Wong RK, Ho KY. Melatonin for the treatment of irritable bowel syndrome. World J Gastroenterol. 2014; 20:2492-2498.
- BahrampourJuybari K, Pourhanifeh MH, et al. Melatonin potentials against viral infections including COVID-19: Current evidence and new findings. Virus Res. 2020; 287:198108.
- Zhang R, Wang X, Ni L, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020; 250:117583.
- Castillo RR, Quizon GRA, Juco MJM, et al. Melatonin as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization (MAC-19 PRO): a case series. Melatonin Research. 2020; 3:297-310.
- Gonçalves AL, Martini Ferreira A, Ribeiro RT, et al. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J NeurolNeurosurg Psychiatry. 2016; 87:1127-1132.
- Peres MF, Zukerman E, da Cunha Tanuri F, et al. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004; 63:757.
- Hurtuk A, Dome C, Holloman CH, et al. Melatonin: can it stop the ringing? Ann OtolRhinolLaryngol. 2011; 120:433-40.
- Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. AnesthAnalg. 2009; 108:1146-1151.
- Samples JR, Krause G, Lewy AJ. Effect of melatonin on intraocular pressure. Curr Eye Res. 1988; 7:649-53.
- Dapagliflozin and Neuro-Nutrition: A Pragmatic Approach to Manage Diabetic Peripheral Neuropathy
Abstract Views :54 |
PDF Views:0
Authors
Affiliations
1 President-Medical & Regulatory Affairs, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, Mumbai, IN
2 Deputy General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, IN
3 Assistant General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, IN
1 President-Medical & Regulatory Affairs, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, Mumbai, IN
2 Deputy General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, IN
3 Assistant General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, IN
Source
The Indian Practitioner, Vol 76, No 2 (2023), Pagination: 28-30Abstract
Diabetic peripheral neuropathy (DPN) is the most prevalent microvascular complication of diabetes mellitus. DPN results from a complex interaction of factors including hyperglycemia, glucotoxicity, increased intracellular glucose concentration-induced mitochondrial dysfunction, oxidative stress, etc. A multifaceted approach is warranted for the clinical treatment of DPN. Combination therapy of an antidiabetic agent along with neuro-nutrition aimed at addressing the pathogenic features of neuropathy can be a potential treatment option for effective management of DPN.Keywords
Type 2 Diabetes (T2DM), Diabetic Peripheral Neuropathy (DPN), Dapagliflozin, Neuro-Nutrition, B-Group Vitamins, Neuroprotection.References
- Zimmet PZ, Diabetes and its Drivers: the Largest Epidemic in Human History? Clin. Diabetes Endocrinol;p.3 (1), 1–8.
- IDF. Diabetes Facts & Figures, the IDF Diabetes Atlas Ninth Edition 2019.
- Bromberg MB, An Approach to the Evaluation of Peripheral Neuropathies. Seminars in Neurology, 25. p. 153-159.
- Maladkar M, Tekchandani C, Dave U; Post-Marketing Surveillance of Fixed Dose Combination of Methylcobalamin, Alpha Lipoic Acid, Folic Acid, Biotin, Benfotiamine & Vitamin B6-Nutripathy for the Management of Peripheral Neuropathy. Journal of Diabetes Mellitus 4. p. 124-132.
- Pugazhenthi S, Qin L, Reddy PH; Common Neurodegenerative Pathways in Obesity, Diabetes, and Alzheimer’s Disease. Biochim. Biophys. Acta Mol. Basis Dis. 1863 (5). p.1037–1045.
- Boulton AJ, Diabetic Neuropathy and Foot Complications. Handb. Clin. Neurol 126. p.97–107. doi:10.1016/B978-0-444-53480-4.00008-4
- Kandeel M. The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis. Front Pharmacol. 2022 Jul 11;13 p 926717.
- Sa-Nguanmoo P, Tanajak P, Kerdphoo S, et al. SGLT2-inhibitor and DPP-4 Inhibitor Improve Brain Function via Attenuating Mitochondrial Dysfunction, Insulin Resistance, Inflammation, and Apoptosis in HFD-Induced Obese Rats. Toxicol. Appl. Pharmacol. 333, p 43–50.
- Duby JJ, Campbell RK, Setter SM, et al. (2004) Diabetic neuropathy: an intensive review. Am J Heal Pharm 61:160–176.
- Cameron NE, Eaton SEM, Cotter MA, et al. (2001) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44, p 1973–1988.
- Obrosova IG (2002) How does glucose generate oxidative stress in peripheral nerve? Int Rev Neurobiol 50, p 3–35.
- World Health Organization (2006) Neurological Disorders: Public Health Challenges. World Health Organization, p 111-174.
- Kumar N. Nutritional Neuropathies. Neurologic Clinics, 25, p 209-255.
- Luo J.J, Sivaraaman K, Nouh A. et al. Elevated Plasma Level of Homocysteine Is an Independent Risk Factor for Peripheral Neuropathy. British Journal of Medicine & Medical Research, 4, p 161-169.
- Caiqin W, Hui P, Wenli W. et al. Effect Of Dapagliflozin Combined With Mecobalamin On Blood Glucose Concentration And Serum MDA, SOD, And Cox-2 In Patients With Type 2 Diabetes Mellitus Complicated With Peripheral Neuropathy. Acta Medica Mediterranea, 35, p 2211.
- Wiciński M, Wódkiewicz E, Górski K, et al. Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury. Pharmaceuticals 2020 Nov 11;13(11) p 379. doi: 10.3390/ph13110379.
- Sun Y, Lai MS. Lu CJ. Effectiveness of Vitamin B12 on Diabetic Neuropathy: Systematic Review of Clinical Controlled Trials. Acta Neurologica Taiwanica, 2005 Jun;14(2). p 48-54.
- Stracke H, Lindemann A, Federlin K. A Benfotiamine-Vitamin B Combination in Treatment of Diabetic Polyneuropathy. Experimental and Clinical Endocrinology & Diabetes, 1996;104(4). p 311-6. doi: 10.1055/s-0029-1211460.